Avestar Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Avestar Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100	Closed	–	–	684
2019 Q2	$0	Buy	100 +45	+82%	+$354	﹤0.01%	957
2019 Q1	$0	Hold	55	–	–	﹤0.01%	961
2018 Q4	$0	Buy	+55	New	+$387	﹤0.01%	972
2018 Q3	–	Sell	-50	Closed	–	–	973
2018 Q2	$0	Buy	+50	New	+$315	﹤0.01%	983

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Avestar Capital's RDY Position: Q3 2019 in Review

Avestar Capital sold out of Dr. Reddy's Laboratories (RDY) in Q3 2019, closing a stake of 100 shares.

Avestar Capital first reported a position in RDY in Q2 2018 and held it in 4 quarters. The position peaked at $0 in Q2 2019. 152 funds tracked by Wall St. Rank hold RDY as of Q3 2019.

Avestar Capital reported no remaining Dr. Reddy's Laboratories position as of Q3 2019 after selling out during the quarter.
Avestar Capital sold 100 Dr. Reddy's Laboratories shares in Q3 2019.
Avestar Capital first reported a position in Dr. Reddy's Laboratories in Q2 2018 and held it in 4 quarters.
Avestar Capital's Dr. Reddy's Laboratories position peaked at $0 in Q2 2019.
152 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.